36.54 USD
↗ 0.49 (1.36%)AT CLOSE (03:59 PM EDT)
Roivant Sciences Ltd. Common Shares
ROIVNASDAQ • USD
36.52
↘ 0.02 (0.04%)
POST MARKET (AS OF 07:55 PM EDT)
Post Market
AS OF 07:55 PM EDT
36.52
↘ 0.02 (0.04%)
Market: CLOSED
Roivant Sciences Ltd. Common Shares (ROIV) trades at $36.57 per share. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Oct 27, 2026.
Open?$35.94
High?$36.83
Low?$35.80
Prev. Close?$36.05
Volume?6.6M
Avg. Volume?7.5M
VWAP?$36.30
Rel. Volume?0.87x
Bid / Ask
Bid?$36.00 × 200
Ask?$37.05 × 100
Spread?$1.05
Midpoint?$36.53
Valuation & Ratios
Market Cap?26.4B
Shares Out?722.3M
Float?502.5M
Float %?69.6%
P/E Ratio?N/A
P/B Ratio?6.24
EPS?-$0.37
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Employees
721
Market Cap
26.0B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2021-10-01
Address
7TH FLOOR, 50 BROADWAY
LONDON, SW1H 0DB
Phone: 441-295-5950
LONDON, SW1H 0DB
Phone: 441-295-5950
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?50
Short Sent.?34
Piotroski F-Score?0/9Weak
Altman Z-Score?41.57Safe
Confidence?58%Low
Short InterestHigh
Short % of Float?8.02%Elevated
Short Interest?40.3M
Days to Cover?7.9
Free Float502.5M
Avg Daily Volume5.1M
Settlement Date2026-10-15
Financial Health
Current Ratio?16.72Strong
Quick Ratio?16.72Strong
Cash Ratio?4.40Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?6.24FAIR▾
Peers100
S&P29
P/S?3,504.21HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-18.4CHEAP▾
S&P97
EV/Sales?3,338.45HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-6.3%WEAK▾
S&P10
ROA?-5.0%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-821063000
Enterprise Value?$25.1B
Fundamentals ratios updated end of day